StockNews.com upgraded shares of Surmodics (NASDAQ:SRDX – Free Report) from a buy rating to a strong-buy rating in a report issued on Tuesday.
Separately, Needham & Company LLC restated a buy rating and issued a $47.00 target price on shares of Surmodics in a report on Wednesday, April 10th.
Read Our Latest Analysis on Surmodics
Surmodics Stock Up 0.4 %
Institutional Trading of Surmodics
Large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC grew its holdings in Surmodics by 305.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 775 shares of the company’s stock valued at $25,000 after buying an additional 584 shares in the last quarter. UBS Group AG lifted its stake in shares of Surmodics by 141.1% in the 3rd quarter. UBS Group AG now owns 2,290 shares of the company’s stock valued at $70,000 after purchasing an additional 1,340 shares during the last quarter. Captrust Financial Advisors lifted its stake in shares of Surmodics by 24.3% in the 1st quarter. Captrust Financial Advisors now owns 2,307 shares of the company’s stock valued at $105,000 after purchasing an additional 451 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Surmodics in the 3rd quarter valued at $87,000. Finally, Citigroup Inc. lifted its stake in shares of Surmodics by 1,023.0% in the 2nd quarter. Citigroup Inc. now owns 4,144 shares of the company’s stock valued at $130,000 after purchasing an additional 3,775 shares during the last quarter. 96.63% of the stock is currently owned by hedge funds and other institutional investors.
Surmodics Company Profile
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Further Reading
- Five stocks we like better than Surmodics
- What to Know About Investing in Penny Stocks
- Comprehensive Analysis of PayPal Stock
- Consumer Discretionary Stocks Explained
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- 3 Monster Growth Stocks to Buy Now
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.